{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T16:14:07Z","timestamp":1795018447731,"version":"4.10.1"},"reference-count":46,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001736","name":"German-Israeli Foundation for Scientific Research and Development","doi-asserted-by":"publisher","award":["G-1413-119.4\/2017"],"award-info":[{"award-number":["G-1413-119.4\/2017"]}],"id":[{"id":"10.13039\/501100001736","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Ethics"],"accepted":{"date-parts":[[2021,7,2]]},"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:p>Recent advances in biomarkers may soon make it possible to identify persons at high risk for late-onset Alzheimer\u2019s disease at a presymptomatic (preclinical) stage. Popular demand for testing is increasing despite the lack of cure and effective prevention options and despite uncertainties regarding the predictive value of biomarker tests. This underscores the relevance of the ethical, cultural and social implications of predictive testing and the need to advance the bioethical debate beyond considerations of clinical consequences. Our qualitative study included three groups of affected persons: People with mild neurocognitive disorder, their relatives and family caregivers of people with dementia. We explored their moral motivations regarding predictive, biomarker-based testing and preclinical diagnostics. We interviewed affected individuals in Germany and Israel (N=88; 44 participants in each country). Transcripts of 12 focus groups and 12 semistructured interviews were content analysed with a focus on the moral motivations of affected persons in their justification of why they accept or reject predictive testing and early diagnosis. We grouped the underlying aspects of moral motivation into four ethical categories: beneficence as a form of personal utility focusing on well-being, the ties of responsibility linking families and their individual members, the importance of self-determination by later life planning and notions of a good life. In general, cultural parallels among these motives were very obvious. Cultural variation occurred mainly in openness to suicide, scepticism about test validity and emphasis on personal autonomy. The study underscores the importance of counselling for life-planning issues and of informing test candidates about problems with test validity and about the ambiguity of test results.<\/jats:p>","DOI":"10.1136\/medethics-2020-106990","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T13:24:38Z","timestamp":1626873878000},"page":"861-867","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Moral motivation regarding dementia risk testing among affected persons in Germany and Israel"],"prefix":"10.1136","volume":"48","author":[{"given":"Z\u00fcmr\u00fct","family":"Alpinar-Sencan","sequence":"first","affiliation":[{"name":"Department for Medical Ethics and History of Medicine, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Niedersachsen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9627-752X","authenticated-orcid":false,"given":"Silke","family":"Schicktanz","sequence":"additional","affiliation":[{"name":"Department for Medical Ethics and History of Medicine, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Niedersachsen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Ulitsa","sequence":"additional","affiliation":[{"name":"Department of Community Mental Health, University of Haifa, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphna","family":"Shefet","sequence":"additional","affiliation":[{"name":"Shalvata Mental Health Care Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perla","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of Community Mental Health, University of Haifa, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"2025092414151622000_48.11.861.1","unstructured":"AbbVie Healthcare Monitor . Attitudes towards Blood Test for Late-Onset Dementia. AbbVie Healthcare Monitor. Available: https:\/\/www.abbvie.de\/content\/dam\/abbvie-dotcom\/de\/documents\/maerz-2018-abbvie-health-care-monitor-altersdemenz.pdf?trackingSelection=Yes [Accessed 22 Jul 2020]."},{"key":"2025092414151622000_48.11.861.2","unstructured":"Rodriguez A . Blood test for beta amyloid may be used to predict alzheimer disease risk. Am J Manag Care, News Room, 2019. Available: https:\/\/www.ajmc.com\/newsroom\/blood-test-for-beta-amyloid-may-be-used-to-predict-alzheimers-disease-risk [Accessed 22 Jul 2020]."},{"key":"2025092414151622000_48.11.861.3","unstructured":"National Institutes of Health . New blood test method may predict Alzheimer\u2019s disease. NIH Research Matters, 2020. Available: https:\/\/www.nih.gov\/news-events\/nih-research-matters\/new-blood-test-method-may-predict-alzheimers-disease [Accessed 22 Jul 2020]."},{"key":"2025092414151622000_48.11.861.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.003"},{"key":"2025092414151622000_48.11.861.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.02.002"},{"key":"2025092414151622000_48.11.861.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2013.01.003"},{"key":"2025092414151622000_48.11.861.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.02.006"},{"key":"2025092414151622000_48.11.861.8","unstructured":"Deuschl G , Maier W . \u201cS3-Leitlinie \u2018Demenzen\u2019 Langversion.\u201d Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN), Deutsche Gesellschaft f\u00fcr Neurologie (DGN). In: Zusammenarbeit MIT Der deutschen Alzheimer Gesellschaft, 2016. https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/038-013l_S3-Demenzen-2016-07.pdf"},{"key":"2025092414151622000_48.11.861.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"2025092414151622000_48.11.861.10","unstructured":"Kolata G . A blood test for alzheimer\u2019s? it\u2019s coming, scientists report: The New York Times, 2019. Available: https:\/\/www.nytimes.com\/2019\/08\/01\/health\/alzheimers-blood-test.html [Accessed 26 Mar 2020]."},{"key":"2025092414151622000_48.11.861.11","unstructured":"Rawlinson K . Alzheimer\u2019s blood test could predict onset up To 20 years in advance. The Guardian, 2019. Available: https:\/\/www.theguardian.com\/society\/2019\/ aug\/02\/alzheimers-test-predicts-onset-up-to-20-years-in-advance [Accessed 26 Mar 2020]."},{"issue":"1","key":"2025092414151622000_48.11.861.12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JAD-170443","article-title":"Prediction and early detection of Alzheimer's dementia: professional disclosure practices and ethical attitudes","volume":"62","author":"Schweda","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2025092414151622000_48.11.861.13","doi-asserted-by":"crossref","DOI":"10.1186\/s12910-020-00476-4","article-title":"Addressing ethical challenges of disclosure in dementia prediction: limitations of current guidelines and suggestions to proceed","volume":"21","author":"Alpinar-Sencan","year":"2020","journal-title":"BMC Med Ethics"},{"issue":"1","key":"2025092414151622000_48.11.861.14","first-page":"61","article-title":"Early diagnosis of Alzheimer\u2019s disease and the use of biomarkers: The views of Israeli experts in the field","volume":"48","author":"Ulitsa","year":"2021","journal-title":"Gerontology and Geriatrics: J Aging Stud"},{"key":"2025092414151622000_48.11.861.15","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2018-104772"},{"key":"2025092414151622000_48.11.861.16","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2013-101887"},{"key":"2025092414151622000_48.11.861.17","unstructured":"World Health Organization [website] . Dementia: number of people affected to triple in next 30 years, 2017. Available: https:\/\/www.who.int\/news-room\/detail\/07-12-2017-dementia-number-of-people-affected-to-triple-in-next-30-years [Accessed 22 Jul 2020]."},{"key":"2025092414151622000_48.11.861.18","unstructured":"World Health Organization . Dementia, 2019. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia [Accessed 22 Jul 2020]."},{"key":"2025092414151622000_48.11.861.19","doi-asserted-by":"crossref","unstructured":"Swinnen A , Schweda M . Popularizing dementia: public expressions and representations of Forgetfulness. Bielefeld: Transcript Verlag, 2015.","DOI":"10.14361\/9783839427101"},{"key":"2025092414151622000_48.11.861.20","doi-asserted-by":"crossref","unstructured":"Werner P , Vermeulen P , Van Gorp B . From history to intervention: a Socio-Cultural analysis of dementia stigma. Dementia and Society, Cambridge Press, 2021.","DOI":"10.1017\/9781108918954.003"},{"key":"2025092414151622000_48.11.861.21","doi-asserted-by":"publisher","DOI":"10.1007\/s11019-011-9321-4"},{"key":"2025092414151622000_48.11.861.22","unstructured":"Involve, 2020. Available: https:\/\/www.invo.org.uk\/ [Accessed 22 Jul 2020]."},{"key":"2025092414151622000_48.11.861.23","doi-asserted-by":"crossref","unstructured":"Raz A , Schicktanz S . Comparative empirical bioethics: dilemmas of genetic testing and euthanasia in Israel and Germany. Springer, 2016. ISBN: 978-3-319-32733-4.","DOI":"10.1007\/978-3-319-32733-4"},{"key":"2025092414151622000_48.11.861.24","unstructured":"Federal Ministry of Education and Research . Kabinett Beschlie\u00dft Nationale Demenzstrategie, 2020. Available: https:\/\/www.bmbf.de\/de\/kabinett-beschliesst-nationale-demenzstrategie-11963.html [Accessed 22 Jul 2020]."},{"key":"2025092414151622000_48.11.861.25","unstructured":"Brodsky J , Bentur N , Laron M . Addressing Alzheimer\u2019s and other types of dementia: Israeli national strategy. Jerusalem: Myers-JDC-Brookdale Institute and Ministry of Health, 2013."},{"issue":"5","key":"2025092414151622000_48.11.861.26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/1049732317736284","article-title":"Methodological and practical issues in cross-national qualitative research: lessons from the literature and a comparative study of the experiences of people receiving a diagnosis of cancer","volume":"28","author":"Chapple","year":"2018","journal-title":"Qual Health Res"},{"key":"2025092414151622000_48.11.861.27","unstructured":"Metschke R , Wellbrock R . Datenschutz in Wissenschaft und Forschung. 3 edn. Berlin: Druckerei Conrad GmbH, 2002."},{"key":"2025092414151622000_48.11.861.28","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"2025092414151622000_48.11.861.29","doi-asserted-by":"publisher","DOI":"10.1177\/1471301218761911"},{"issue":"3","key":"2025092414151622000_48.11.861.30","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/1471301218777443","article-title":"The process of disclosing a diagnosis of dementia and mild cognitive impairment: a national survey of specialist physicians in Denmark","volume":"19","author":"Nielsen","year":"2020","journal-title":"Dementia"},{"key":"2025092414151622000_48.11.861.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2008.09.020"},{"key":"2025092414151622000_48.11.861.32","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmg407"},{"key":"2025092414151622000_48.11.861.33","unstructured":"Beauchamp TL , Childress JF . Principles of biomedical ethics. 6 edn. New York: Oxford University Press, 2009."},{"key":"2025092414151622000_48.11.861.34","doi-asserted-by":"publisher","DOI":"10.1023\/B:MHEP.0000021844.57115.9d"},{"key":"2025092414151622000_48.11.861.35","doi-asserted-by":"publisher","DOI":"10.1023\/B:MHEP.0000021849.57115.eb"},{"issue":"5","key":"2025092414151622000_48.11.861.36","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/03605310500253030","article-title":"Empirical ethics, context-sensitivity, and contextualism","volume":"30","author":"Musschenga","year":"2005","journal-title":"J Med Philos"},{"key":"2025092414151622000_48.11.861.37","doi-asserted-by":"publisher","DOI":"10.1188\/14.ONF.545-547"},{"issue":"3","key":"2025092414151622000_48.11.861.38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12376-011-0070-8","article-title":"The diversity of responsibility: the value of Explication and Pluralization","volume":"3","author":"Schicktanz","year":"2012","journal-title":"Med Stud"},{"key":"2025092414151622000_48.11.861.39","unstructured":"Taylor C . Sources of the self: the making of the modern identity. Cambridge, MA: Harvard University Press, 1989."},{"key":"2025092414151622000_48.11.861.40","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-016-0227-5"},{"issue":"1","key":"2025092414151622000_48.11.861.41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11673-019-09901-9","article-title":"Stakeholders' views on early diagnosis for Alzheimer's disease, clinical trial participation and amyloid PET disclosure: a focus group study","volume":"16","author":"Vanderschaeghe","year":"2019","journal-title":"J Bioeth Inq"},{"issue":"2","key":"2025092414151622000_48.11.861.42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3233\/JAD-170813","article-title":"Perspectives on communicating biomarker-based assessments of Alzheimer's disease to cognitively healthy individuals","volume":"62","author":"Milne","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2025092414151622000_48.11.861.43","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-016-0223-9","article-title":"Desire for predictive testing for Alzheimer's disease and impact on advance care planning: a cross-sectional study","volume":"8","author":"Sheffrin","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"2025092414151622000_48.11.861.44","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2015-103057"},{"issue":"1","key":"2025092414151622000_48.11.861.45","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamaneurol.2017.2954","article-title":"Comprehension of an elevated amyloid positron emission tomography biomarker result by cognitively normal older adults","volume":"75","author":"Mozersky","year":"2018","journal-title":"JAMA Neurol"},{"key":"2025092414151622000_48.11.861.46","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200212000-00012"}],"container-title":["Journal of Medical Ethics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/medethics-2020-106990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T21:15:29Z","timestamp":1758748529000},"score":1,"resource":{"primary":{"URL":"https:\/\/jme.bmj.com\/lookup\/doi\/10.1136\/medethics-2020-106990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":46,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,10,31]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1136\/medethics-2020-106990"],"URL":"https:\/\/doi.org\/10.1136\/medethics-2020-106990","relation":{},"ISSN":["0306-6800","1473-4257"],"issn-type":[{"value":"0306-6800","type":"print"},{"value":"1473-4257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,21]]}}}